Kyntra Bio (KYNB) Cash & Equivalents (2014 - 2026)

Kyntra Bio has reported Cash & Equivalents for 13 years, with the latest figure at $37.0 million in Q1 2026.

• Quarterly Cash & Equivalents rose 2038.55% year-over-year to $37.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.0 million (up 2038.55% YoY) and the FY2025 annual result came in at $47.9 million, down 53.15% from the prior year.
• Cash & Equivalents declined to $37.0 million in Q1 2026 per KYNB's latest filing, from $47.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $188.5 million in Q1 2023 and troughed at $1.7 million in Q1 2025.
• A 5-year average of $107.8 million and a median of $120.9 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents plunged 98.66% in 2025, then jumped 2038.55% in 2026.
• Over 5 years, Cash & Equivalents stood at $155.7 million in 2022, then declined by 26.98% to $113.7 million in 2023, then retreated by 10.12% to $102.2 million in 2024, then slumped by 53.15% to $47.9 million in 2025, then retreated by 22.72% to $37.0 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $37.0 million, $47.9 million, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.